Home Drug IndexClinical Monograph

Nipradilol Uses, Dosage, Side Effects & Safety | DrugsAtlas

Authoritative Clinical Reference

DRUG NAME: Nipradilol

Therapeutic Class: Antiglaucoma Agent

Subclass: Non-selective Beta-blocker with Nitric Oxide-donating Activity

Specialty: Ophthalmology

Schedule (India): Schedule H

Route(s): Ophthalmic

Formulations Available in India:
• Eye drops: 0.25% w/v
• Eye drops: 0.5% w/v

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

Indication	Starting Dose	Titration	Maintenance Dose	Maximum Dose	Clinical Notes
Primary Open-angle Glaucoma	1 drop of 0.25% in affected eye(s) twice daily	Increase to 0.5% formulation after 2–4 weeks if IOP reduction inadequate	1 drop twice daily (0.25% or 0.5%)	1 drop of 0.5% twice daily per eye	Assess IOP response at 2–4 weeks; apply nasolacrimal occlusion post-instillation
Ocular Hypertension	1 drop of 0.25% in affected eye(s) twice daily	Increase to 0.5% formulation based on IOP response	1 drop twice daily (0.25% or 0.5%)	1 drop of 0.5% twice daily per eye	May be used as monotherapy or in combination with prostaglandin analogues or carbonic anhydrase inhibitors

Combination Therapy Notes:
• Compatible with prostaglandin analogues, carbonic anhydrase inhibitors, and alpha-2 agonists
• Maintain minimum 5-minute interval between different eye drops

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Notes	Evidence
Normal Tension Glaucoma — OFF-LABEL	1 drop of 0.25% or 0.5% twice daily	Specialist only; nitric oxide-mediated vasodilation may benefit optic nerve perfusion	Limited international data (Japanese studies); not standard practice in India

PAEDIATRIC DOSING (Specialist Only)

Primary Indications:
• NOT APPROVED for routine paediatric use in India
• Safety and efficacy not established in children

Secondary Indications — Paediatrics (Off-label, if any):

Age Group	Indication	Dose	Notes
≥2 years	Congenital/developmental glaucoma — OFF-LABEL	0.25% eye drops, 1 drop in affected eye(s) twice daily	Specialist only; paediatric ophthalmologist supervision mandatory
<2 years	Not recommended	—	Use only in exceptional circumstances under tertiary centre protocol

Safety Monitoring in Paediatrics:
• Monitor for systemic beta-blockade: bradycardia, bronchospasm, hypotension
• Assess heart rate before and after initiation
• Nasolacrimal occlusion essential to minimize systemic absorption
• Limited Indian data available

RENAL ADJUSTMENT

• No dosage adjustment required (topical ophthalmic administration)
• Systemic absorption minimal with proper technique
• Exercise caution in severe renal impairment if patient on concurrent nephrotoxic medications

HEPATIC ADJUSTMENT

Child-Pugh Class	Recommendation
Class A (Mild)	No dose adjustment required
Class B (Moderate)	No dose adjustment required; monitor for systemic effects
Class C (Severe)	Use with caution; monitor for systemic beta-blockade effects (bradycardia, hypotension)

CONTRAINDICATIONS

• Sinus bradycardia (<50 beats per minute)
• Second-degree or third-degree atrioventricular block (without pacemaker)
• Sick sinus syndrome (without pacemaker)
• Cardiogenic shock
• Decompensated heart failure
• Bronchial asthma or history of bronchospasm
• Severe chronic obstructive pulmonary disease
• Hypersensitivity to nipradilol or any formulation component

CAUTIONS

• Controlled chronic obstructive pulmonary disease — risk of bronchospasm even with topical use
• Diabetes mellitus — may mask hypoglycaemic symptoms (tachycardia, tremor)
• Peripheral vascular disease
• Thyrotoxicosis — may mask tachycardia
• Myasthenia gravis — potential worsening of muscle weakness
• Concurrent systemic beta-blockers or non-dihydropyridine calcium channel blockers
• Pre-existing corneal disease — risk of dry eye exacerbation or keratitis
• Depression history — monitor for mood changes
• First-degree AV block — monitor for progression

PREGNANCY

Parameter	Details
Risk summary	Limited human data; avoid especially in first trimester
Preferred alternatives	Brimonidine (safe in 2nd/3rd trimester); betaxolol (if beta-blocker necessary)
When may be used	Only if clearly indicated and benefit outweighs risk; specialist supervision required
Monitoring	Fetal growth; neonatal bradycardia and hypoglycaemia if used near term

LACTATION

Parameter	Details
Compatibility	Likely compatible — minimal systemic absorption with topical ophthalmic use
Preferred alternatives	Betaxolol if beta-blocker needed
Drug level in milk	Expected to be very low
Infant monitoring	Bradycardia, lethargy, poor feeding, inadequate weight gain
Administration advice	Apply nasolacrimal occlusion for 1–2 minutes post-instillation to reduce systemic absorption

ELDERLY

• Starting dose: 0.25% eye drops, 1 drop twice daily (same as adult dosing)
• Titration: Increase to 0.5% based on IOP response and tolerability
• Special considerations:

Higher risk of systemic beta-blockade effects due to reduced hepatic/renal reserve
Monitor heart rate and blood pressure periodically
Assess for orthostatic hypotension
Increased dry eye prevalence — confirm good corneal health before initiation
Verify adequate manual dexterity for self-administration

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect	Recommendation
Systemic beta-blockers (atenolol, metoprolol, propranolol)	Additive cardiac depression; excessive bradycardia and hypotension	Avoid combination if possible; if essential, monitor heart rate and blood pressure closely
Verapamil, Diltiazem	Risk of severe bradycardia, AV block, heart failure	Avoid concurrent use with systemic formulations
Clonidine	Risk of rebound hypertensive crisis upon clonidine withdrawal	If discontinuing clonidine, taper gradually while continuing nipradilol
Amiodarone, other Class III antiarrhythmics	Additive cardiac depressant effects; risk of bradycardia	Avoid combination; if essential, close ECG and heart rate monitoring required

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect	Recommendation
Insulin, sulfonylureas	May blunt recognition of hypoglycaemic symptoms	Monitor blood glucose closely; counsel diabetic patients
Prostaglandin analogues (latanoprost, bimatoprost)	Acceptable combination for additive IOP reduction	Monitor IOP; maintain 5-minute gap between instillations
Topical ocular corticosteroids	May attenuate IOP-lowering effect	Monitor IOP closely when used concurrently
Digoxin	Additive bradycardia	Monitor heart rate
Other topical antiglaucoma agents	Potential additive systemic effects	Space instillations at least 5 minutes apart

COMMON ADVERSE EFFECTS

• Ocular stinging or burning on instillation
• Eye irritation
• Dry eye sensation
• Transient blurred vision
• Conjunctival hyperaemia
• Foreign body sensation
• Mild headache (transient)

SERIOUS ADVERSE EFFECTS

• Symptomatic bradycardia — requires discontinuation and cardiology review
• Bronchospasm — especially in patients with undiagnosed reactive airway disease; discontinue immediately
• Severe hypotension
• Syncope
• Worsening of heart failure
• Corneal erosions or persistent epitheliopathy with prolonged use
• Severe allergic reaction (angioedema, anaphylaxis) — rare; discontinue immediately
• Depression (rare with prolonged use)

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	Intraocular pressure, visual acuity, optic nerve assessment, heart rate, blood pressure, corneal health evaluation
After initiation/dose change	Recheck IOP at 2–4 weeks; assess systemic vitals (heart rate, blood pressure)
Long-term	IOP and optic nerve status every 3–6 months; corneal and ocular surface assessment; periodic heart rate and blood pressure monitoring especially in elderly or those on systemic beta-blockers

BRANDS AVAILABLE IN INDIA

• Nipradil Eye Drops (Intas)
• Generic nipradilol eye drops (various manufacturers)

Note: Limited brand availability compared to timolol; may require specific pharmacy sourcing

PRICE RANGE (INR)

Formulation	Approximate Price
0.25% eye drops (5 mL)	₹100–150 per bottle
0.5% eye drops (5 mL)	₹120–180 per bottle

• Not included in current NLEM; not under NPPA price control
• Limited availability in government supply chains

CLINICAL PEARLS

• Nitric oxide-donating property provides additional vasodilatory benefit to optic nerve head perfusion — particularly useful in normal tension glaucoma
• Consider switching from timolol to nipradilol when additional vasoactive benefit is desired without changing drug class
• Nasolacrimal occlusion for 1–2 minutes post-instillation is essential to minimize systemic absorption and enhance local efficacy
• Avoid in asthmatics regardless of disease severity — systemic absorption via nasal mucosa can trigger bronchospasm
• Monitor for dry eye with chronic use; corneal toxicity may occur with prolonged therapy
• When IOP control is inadequate, combination with prostaglandin analogues or carbonic anhydrase inhibitors is effective

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.